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Background: Human papillomaviruses (HPV) are oncogenic and mainly associated with cervical cancers. Recent
evidence has demonstrated HPV infection in other tissues, including oral epithelia and mucosa. Although a recent
pilot study provided new information about oral HPV status in healthy adults from Nevada, no information was
obtained about oral HPV prevalence among children or teenagers, therefore, the goal of this study is to provide
more detailed information about oral prevalence of high-risk HPV among children and teenagers in Nevada.
Methods: This retrospective study utilized previously collected saliva samples, obtained from pediatric dental clinic
patients (aged 2 – 11) and local school district teenagers (aged 12-17) for high-risk HPV screening (n=118) using
qPCR for quantification and confirmation of analytical sensitivity and specificity.
Results: A small subset of saliva samples were found to harbor high-risk HPV16 (n=2) and HPV18 (n=1),
representing a 2.5% of the total. All three were obtained from teenage males, and two of these three samples were
from White participants.
Conclusions: Although this retrospective study could not provide correlations with behavioral or socioeconomic
data, this project successfully screened more than one hundred saliva samples for high-risk HPV, confirming both
HPV16 and HPV18 strains were present in a small subset. With increasing evidence of oral HPV infection in children,
this study provides critical information of significant value to other dental, medical, oral and public health
professionals who seek to further an understanding of oral health and disease risk in pediatric populations.
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The human papillomaviruses (HPV) encompass a closely
related family of DNA viruses, which are capable of inte-
grating into the human genome to drive transformation
of infected epithelia [1-4]. Much of the epidemiological
evidence for HPV-driven carcinogenesis, as well as the
biological mechanisms, have been derived from studies
of cervical cancers [5-7] that isolated high-risk HPV
from both adeno- and squamous cell carcinomas [6-9].
Although high-risk HPV drives the transformation and* Correspondence: karl.kingsley@unlv.edu
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reproduction in any medium, provided the ormalignancy process of nearly all cervical cancers, HPV
infection is now known to modulate epithelial trans-
formation in breast, lung, penile, anal, and also oral tis-
sues [10-20].
The primary risk factors for oral carcinogenesis are
tobacco and alcohol use, although new lines of evidence
now suggest HPV may also be an independent risk fac-
tor [17-23]. The higher prevalence of high-risk HPV
strains in pre-cancerous and cancerous oropharyngeal
tumors suggests that HPV may preferentially infect
developing or established cancers, thereby modulating
carcinogenic progression and ultimately influencing
health outcomes [24-26]. In fact, some evidence has sug-
gested that high-risk HPV infection may be associatedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rates [27-29], while conflicting reports have demon-
strated significantly decreased patient survival [30-32] or
have observed no discernable and statistically significant
effects [33].
Despite the conflicting nature of these results, it is
clear that HPV may be involved in modulating tumor re-
sponsiveness and carcinogenic progression, therefore
many of these studies have provided valuable epidemio-
logical information regarding which high-risk HPV
strains are most often implicated in these cases [34-36].
These studies have revealed HPV16, and HPV18 to a
lesser extent, accounted for the overwhelming majority
(71-94.7%) of high-risk oral HPV detected [17,18,21-
23,34-36]. Moreover, new evidence now suggests that
these specific high-risk HPV strains (HPV16 and
HPV18), may initiate oral carcinogenesis among the
smaller fraction of oral cancer patients who do not con-
sume alcohol or use tobacco [37,38].
Based upon the findings of oral HPV in non-tobacco
and non-alcohol associated oral cancers, other recent
efforts have focused more specifically to evaluate oral
HPV prevalence and transmission within healthy popu-
lations, which also confirmed that HPV16 and HPV18
were the most commonly detected oral high-risk HPV
strains [39-41] among healthy adults.
To this end, a recent pilot study evaluating oral HPV
among healthy adults was performed in Nevada [42], a
state recently documented with rising rates of oropha-
ryngeal cancers, in stark contrast to the declining rates
observed in neighboring states and the US more gener-
ally [43,44]. This study revealed the presence of high-
risk strain HPV16, but not HPV18, among females and
minorities, the only population subgroups demonstrated
to have rising orpharyngeal cancer rates – despite the
overall declining rates observed within the general popu-
lation [45-47]. This study utilized a saliva-based screen-
ing procedure, part of a growing trend towards less
invasive methodologies, such as oral lavage- and saliva-
based screenings, to analyze oral HPV status among
healthy adult patients [48-51].
Although prevalence rates ranged widely, these studies
have suggested that oral HPV infection may be increasing,
not only among adults, but more specifically among
younger adults, teenagers, and children [52-54].To this
end, some studies have examined oral HPV in children or
adolescents, although many of these focused primarily on
children with underlying medical conditions, such as
co-infection with human immunodeficiency virus (HIV)
[55-57]. Most other research, however, has focused more
specifically on elucidating the role of vertical HPV trans-
mission in newborns, demonstrating the potential to ac-
quire high-risk HPV during the delivery and birthing
process, although these infections typically resolve [58-63].However, new evidence is emerging that demonstrated
high-risk oral HPV infection in normal, healthy children,
with the highest rates observed among children under 7
years old (7.9%-8.7%), and declining rates observed
among healthy adolescents (13-20 years old; 5.1%-5.2%)
and healthy adults (3.5%) [64,65]. These observations
may suggest that oral HPV infection may occur through
close personal contact with family members or through
contact with fomites and other vectors at daycare cen-
ters, preschool or in primary education settings, with
most children immunologically competent to resolve
these infections [66]. However, some infections may per-
sist and their contribution to the development of oral
cancers and other pathologies remains unclear.
Although a pilot study was recently conducted to
evaluate oral HPV status, this involved only healthy adult
patients - with no information obtained about oral HPV
prevalence among children or teenagers. Based upon the
previous evidence demonstrating some level of oral HPV
infection in healthy children and adolescents, combined
with the lack of data about this population more specif-
ically, the goal of this current study is to provide more
detailed information about prevalence of high-risk HPV
strains HPV16 and HPV18 in the oral cavity of children
and teenagers in Nevada.
Results
The proportion of female and male specimens from the
study sample was not statistically different from the
overall proportions within the local community of Clark
County, Nevada (Table 1). More specifically, the percent-
age of females and males in the sample was approxi-
mately equal (51.7% and 48.3%, respectively), which was
not significantly different than the local area population
(p = 0.7051). The proportion of minority (non-White)
samples was much greater in the study sample (70.3%)
than in the local population (39.1%), which was statisti-
cally significant (p < 0.0001). Although data from the
local population were unavailable for age-specific com-
parisons, the study sample was comprised more from
younger children (ages 2-11: 59.3%) than from adoles-
cents and teenagers (12-17: 40.7%).
Detailed analysis of saliva samples revealed some vari-
ability between cell counts, DNA concentration and DNA
purity between samples (Figure 1). Cell counts varied
between a 0.8 – 2.3 x 106 cell/mL, which were further cate-
gorized into low (0.8 – 1.4 x 106) and high (1.6 – 2.3 x 106)
cell counts. DNA was successfully isolated from all saliva
samples, with the average DNA concentration for samples
observed at 842.7 ng/μL. Samples from each cohort
(CCSD, UNLV) with cell counts in the low category were
found to have lower average concentrations of DNA than
samples from the same cohort with cell counts in the high
category. Absorbance measurements and A260/A280 ratio
Table 1 Demographic analysis of study participants
CCSD (n=48) UNLV-SDM (n=70) Total sample (n=118) Clark County population Statistical analysis
Gender
Female n = 30 (62.5%) n = 31 (44.3%) n = 61 (51.7%) n = 969,781 (49.7%) χ2 = 0.17849 d.f. = 1
Male n = 18 (37.5%) n = 39 (55.7%) n = 57 (48.3%) n = 981,488 (50.3%) p = 0.7051
Race
White n = 12 (25%) n = 23 (32.9%) n = 35 (29.7%) n = 1,188,323 (60.9%) χ2 = 28.3634 d.f. = 1
Non-White n = 36 (75%) n = 47 (67.1%) n = 83 (70.3%) n = 762,946 (39.1%) p < 0.0001
Age
2-11 n = 0 (0%) n = 70 (100%) n = 70 (59.3%) N/A
12-17 n = 48 (100%) n = 0 (0%) n = 48 (40.7%) N/A
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approximately equal between cohorts, as well as between
samples in the low- and high-cell count categories.
Samples of extracted DNA were subsequently screened
for the presence of HPV16 and HPV18 using PCR
(Figure 2). This screening yielded three HPV-positive
samples (n = 3/118), representing 2.5% of the total
screened. Two of these samples (S5, S38) harbored
HPV16 DNA and one was found to harbor HPV18 DNAA
B
C
CCSD (n=48) n = 17*                 n=31*
[DNA]        707.1 ng/μl           859.4 ng/μl
A260/A280        1.71                      1.74
UNLV (n=70) n = 52                   n=18
[DNA]         886.3 ng/μl           910.2 ng/μl
A260/A280        1.82                      1.79
Total (n=118) n = 69                   n=49
[DNA]         825.9 ng/μl           875.8 ng/μl
A260/A280         1.77                      1.76




Figure 1 Saliva sample analysis: cell count, DNA isolation and
purity. A) Following centrifugation and cell resuspension in saline,
cell number for each sample was determined revealing three-fourths
of the UNLV samples were observed to have lower cell counts
(0.8-1.4 x 106 cells/mL) while only one-third of CCSD sample were
estimated* to have lower cell counts. B) DNA concentrations were
found to be higher from the high-cell count samples within each
cohort (CCSD: 859.4 and 707.1 ng/μL, respectively; UNLV: 886.3 and
910.2 ng/μL, respectively). DNA purity averaged between 1.71 and
1.82. C) Equal concentrations of extracted DNA (1 μL) was screened
using GAPDH, which revealed no considerable variation in band
intensity between cohorts of samples from high- and low-cell count
categories.(S7). Processing of DNA samples using qPCR provided
quantitative assessments, as well as measurements of
sensitivity and specificity. Analysis of copy number per
genome for the housekeeping gene (β-actin) for the
HPV-positive (range: 25 - 40 copies/genome) and HPV-
negative samples (4 – 93 copies/genome) revealed values
that were well above the cutoff value (> 0.1 copies/genome).
Results of qPCR analysis revealed copy numbers of
HPV-positive samples (range: 150 – 880 copies/gen-
ome) that were significantly higher than HPV-negative
samples (range: 0.00148 – 0.0000016 copies/genome),
which could be distinguished using the cutoff value
(> 0.001 copies/genome). These analyses revealed no
false positives or false negatives, demonstrating suffi-
cient sensitivity and specificity to ascertain the propor-
tion of true HPV-positive samples (3/118 or 2.5%; 3/3
or 100%) and true HPV-negative samples (115/118 or
97.5%; 115/115 or 100%).
Although the relatively small proportion of HPV-
positive samples does not allow for more broad infer-
ences, a descriptive analysis of the demographic infor-
mation regarding these samples revealed that all three
were derived from males (n=3/57 or 5.3%) and none
were derived from females. The two HPV16-positive
samples were collected from White participants aged 14
(n = 2/35 or 5.7%), while the HPV18-positive sample
was collected from a non-White participant aged 15
(n = 1/83 or 1.2%). All three HPV-positive samples were
from the CCSD (teenage) cohort (n = 3/48 or 6.25%),
while none were observed in the UNLV-SDM (pediatric)
cohort (n = 70).
Discussion
The main goal of this study was to screen normal
healthy children and teenagers in Nevada for the pres-
ence of high-risk oral HPV. This retrospective analysis
used existing saliva samples, collected from pediatric
dental patients and local school district teenagers, to
obtain novel data from this previously untested juvenile
population thereby complementing the ever-growing
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β actin HPV16 HPV18
Sample (copy#/genome) (copy#/genome) (copy#/genome)
S5 40 150 0.00004
S38 51 290 0.0001
S7 25 0.0009 880
HPV16 positive HPV18 positive HPV negative
Male n = 2/57 (3.5%) n = 1/57 (1.8%) n = 54/57 (94.7%)
White n = 1/35 (2.9%) n = 1/35 (2.9%) n = 33/35 (94.3%)
Other n = 1/83 (1.2%) n = 0 n = 82/83 (98.8%)
Age12 17 n = 2/48 (4.2%) n = 1/48 (2.1%) n = 45/48 (93.7%)
Figure 2 Saliva sample screening: analysis of qPCR HPV results. A) Three samples were found to harbor HPV DNA: HPV16-positive samples
(S5, S38); One sample was HPV-positive (S7). B) qPCR analysis revealed HPV-positive samples had values well above the established cutoff value
(> 0.001 copies/genome). C) All three HPV-positive samples were male, representing 2.5% of the total (n = 118). Two of the three HPV-positive
samples were from White participants. All three HPV-positive samples were from the CCSD cohort (ages: 12-17); Both HPV16-positive samples
were obtained from 14-year old participants, while the HPV18-positive sample was obtained from a 15-year old.
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dren. Most importantly, these data have suggested an oral
prevalence of high-risk HPV stains of approximately 2.5%.
Recent studies of healthy adults have found similar
prevalence rates, ranging between 3.1 and 5% [40,41]. In
fact, the recent pilot study of healthy adults in Nevada
reported oral HPV in 2.6% of 151 cancer-free patients
[42]. The results of the current study were markedly dif-
ferent, however, because two of the three HPV-positive
samples were obtained from Whites and all were from
males – whereas the prior study of adults found oral HPV
among females and minorities only. Other evidence has
suggested that although samples from females and males
had similar rates of oral HPV (56 and 44%, respectively),
the HPV-negative samples from that study were over-
whelmingly female (82%) – providing some evidence of a
possible male, gender-specific phenomenon similar to the
current study results [67]. Although there are manypossible explanations, such as the transient nature of the
local population, many other factors such as stress, diet,
income, poverty, socioeconomic status, and oral HPV
exposure may affect different racial groups and both
genders in similar ways.
This study represents a significant turning point in
public health efforts to elucidate oral HPV detection in a
geographic area known for higher than average (and pre-
viously increasing) rates of oropharyngeal cancers
[43,44]. However, this study had several limitations that
must be acknowledged. First, the retrospective nature of
this study limited the inferences that could be made, un-
like other recent prospective studies of oral HPV in chil-
dren and adolescents [64-68]. In addition, no detailed
behavioral or socioeconomic data were available, such as
parental income or smoking behaviors, due to the nature
of this retrospective pilot study. It is hoped that future
investigations involving oral HPV will provide additional
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well as data regarding housing, education, income and
other socioeconomic indicators [67-71].
Conclusions
This project successfully screened saliva samples for
high-risk HPV, confirming both HPV16 and HPV18
strains were present in a small subset. Although previous
work has focused on oral HPV transmission from
mother to newborn during birth and while nursing
[58-63,68], there is growing evidence to suggest that fol-
lowing the perinatal period, oral HPV transmission
through close personal contact, such as shared eating
utensils, toys, kissing and bathing may account for oral
HPV transmission (primarily HPV16) in children and
adolescents [72-75]. This study, therefore, provides crit-
ical information of significant value to other dental,
medical, oral and public health professionals who seek
to further an understanding of high-risk HPV prevalence
among children as part of a broader understanding of
oral health and disease risk in pediatric populations.
Methods
Sample size
Given the known prevalence of high-risk oral HPV in
the previous study that screened healthy adults within
this geographic area, the appropriate sample size was
calculated using the following formula: n = Z2 P (1 – P)
/ d2, where n = sample size, Z = Z statistic for a level of
confidence, P = expected prevalence, and d = precision
[76,77]. Using the 95% level of confidence, the Z value
was determined to be 1.96; Using the previous propor-
tion/prevalence of high-risk HPV of 2.6%, the P value
was set as P = 0.026; The value for d should be calcu-
lated at 0.5 (P), resulting in a value for d = 0.013. Using
these inputs, the minimum sample size for this study
was calculated to be n = 75.
Human subjects
The protocol for this study titled “Retrospective Evalu-
ation of Microbial Presence in Existing Saliva Repo-
sitory: A PCR-Based Molecular Survey of Oral Microbial
Populations from Existing Saliva Samples” was filed,
amended, and approved by the UNLV Office of Research
Integrity – Human Subjects (OPRS#1104-3801M) on
May 10, 2011. The existing saliva samples were collected
during two previous studies within the UNLV School of
Dental Medicine (SDM) during 2009-2010. Saliva sam-
ples collected from a prior study of teenagers (14-15
years old) were derived from a convenience sample of
selected schools within the Clark County, Nevada School
District (CCSD; n=48); originally obtained for the pur-
pose of surveying levels of oral cariogenic bacteria. Saliva
samples collected from young children (2-11 years old)were obtained from a convenience sample within the
UNLV-SDM pediatric dental clinic (n=70); originally
obtained for the purpose of screening for heavy metal
(lead or Pb) burden. In brief, for the original saliva sam-
ple collections at CCSD and UNLV-SDM, parents and
subjects were recruited onsite. Inclusion criteria: Informed
Consent/Parent Permission was required and conducted
onsite, as well as an Assent to Participate in Research for
all children over the age of seven who were capable of
reading. Exclusion criteria: subjects younger than seven
years of age, subjects that declined to participate, and sub-
jects with parents who declined to participate. Each sam-
ple was assigned a unique, randomly-generated number to
prevent research bias, with the only demographic informa-
tion regarding the saliva specimens: gender, age, and eth-
nicity of the original study participant. This current
project was a retrospective analysis of these two collec-
tions of saliva samples; the total combined sample size for
this study was n = 118.
Saliva collection protocol
In brief, subjects who agreed to participate were given a
small, sterile saliva collection container, 50 mL sterile
polypropylene tube (Fisher Scientific: Fair Lawn, New
Jersey, USA). Participants were then asked to chew on a
small piece of paraffin wax for one minute and then to
expectorate, in accordance with the previous pilot study
protocol [42]; sample volumes varied from approxi-
mately 50 μL to 2.5 μL. Samples were stored on ice
until transport to a biomedical laboratory for analysis.
Each saliva sample was assigned a unique, randomly-
generated number to prevent research bias. Demogra-
phic information regarding the sample was concurrently
collected, which consisted of age, gender, and ethni-
city only.
Cell counting and DNA isolation
All samples were centrifuged for 10 minutes at 2,100 g
(RCF) and the cell pellet washed with 1X phosphate-
buffered saline (PBS) (HyClone: Logan, Utah, USA) and
resuspended in 5 mL of 1X PBS. Cell number was deter-
mined using Trypan Blue (Fisher Scientific: Fair Lawn,
New Jersey, USA) using a Zeiss Axiovert 40 inverted
microscope (Carl Ziess, Inc: Thornwood, New York,
USA) and a hemacytometer (Fisher Scientific: Fair Lawn,
New Jersey, USA). To determine if any samples harbored
the HPV virus, DNA was isolated from the saliva sample
using a minimum of 3.5 x 105 cells using the Genomic-
Prep DNA isolation kit (Amersham Biosciences:
Buckinghamshire, United Kingdom), using the proced-
ure recommended by the manufacturer as previously
described [12,42,78,79]. DNA purity was calculated using
ratio measurements of absorbance at 260 and 280 nm
(A260/A280 ratio between 1.7 and 2.0).
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DNA from each sample was then used to perform PCR
with the Fisher exACTGene complete PCR kit (Fisher
Scientific: Fair Lawn, New Jersey, USA) and a Mastercy-
cler gradient thermocycler (Eppendorf: Hamburg,
Germany) using the following primers for HPV16 [12,78],
HPV18 [12,78,79], and glyceraldehyde- 3- phosphate
dehydrogenase (GAPDH) [80] (SeqWright: Houston,
Texas, USA):
HPV16 forward primer, ATGTTTCAGGACCCACA
GGA;
HPV16 reverse primer, CCTCACGTCGCAGTAAC
TGT.
HPV18 forward primer, ATGGCGCGCTTTGAGGA
TCC;
HPV18 reverse primer, GCATGCGGTATACTGTC
TCT;
GAPDH forward primer, ATCTTCCAGGAGCGAGA
TCC;
GAPDH reverse primer, ACCACTGACACGTTGGC
AGT;
One μg of template DNA was used for each reaction.
The initial denaturation step ran for three minutes at
94°C. A total of 30 amplification cycles were run, con-
sisting of 30 second denaturation at 94°C, 60 seconds of
annealing at 58°C, and 30 seconds of extension at 72°C.
Final extension was run for five minutes at 72°C. The
PCR reaction products were separated by gel electro-
phoresis using Reliant 4% NuSieveW 3:1 Plus Agarose
gels (Lonza: Rockland, Maine, USA). Bands were visua-
lized by UV illumination of ethidium-bromide-stained
gels and captured using a Kodak Gel Logic 100 Imaging
System and 1D Image Analysis Software (Eastman
Kodak: Rochester, New York, USA).
Quantitative PCR (qPCR)
DNA samples were then processed using qPCR to pro-
vide more specific and sensitive quantification. Primers
and probes were designed using Roche Universal Probe
library (UPL) assay design software to amplify the region
overlapping E6 and E7 gene sequence of HPV16 (Gen-
Bank accession no. K02718) and the human β-actin
housekeeping gene (GenBank accession no. M10277).
These primers were purchased from Sigma-Aldrich
(St. Louis, Missouri, USA) and probes from Roche Applied
Science (Indianapolis, Indiana, USA).
HPV16 E6/E7 forward primer 50-CAACTGATCTC
TACTGTTATGAGCAA-30, HPV16 E6/E7 reverse primer
50-CCAGCTGGACCATCTATTTCA-30, HPV16 E6/E7
hydrolysis “Taqman” probe 50-(fam)-AGGAGGAG-(dark
quencher dye)-30 (UPL probe #63) was used to amplify the
73 base pair (bp) region between the 535 nucelotide (nt)
position and 607 nt position. HPV18 E7 forward primer
50-GACTCAGAGGAAGGAAAACGATGAAA, HPV18E7 reverse primer 50-GTGACGTTGTGGTTCGGCT;
HPV18 E7 probe 50-TGGAGTTAATCATCAACATT
TACCA was used to amplify the 25 bp region between the
715 and 739 nt position. Human β-actin forward pri-
mer 50-GTGGGGTCCTGTGGTGTG-30, human β-actin
50-GAAGGGGACAGGCAGTGA-30, human β-actin hy-
drolysis “Taqman” probe 50-(fam)-GGGAGCTG-(dark
quencher dye)-30 (UPL probe #24) amplified the 61 bp
region between 2642 nt position and 2702 nt position.
The real-time reaction mixture was prepared in a
LightCyclerW 480 multiwell Plate 96 containing 1x Light-
CyclerW 480 Probes Master (Roche Applied Sciences: In-
dianapolis, Indiana, USA), 1 μM of each respective
primer set (forward and reverse), 0.2 μM of respective
probe, and 2 μl of DNA template; in a 20 μl final reac-
tion volume. The probes master mix contained reaction
buffer, dNTP mix (including dUTP in place of dTTP),
3.2 mM MgCl2, and Taq DNA polymerase. The real-
time PCR assay was performed on a LightCycler 480 sys-
tem (Roche Applied Sciences: Indianapolis, Indiana,
USA) with the following cycle parameters: pre-
incubation for initial enzyme activation at 95°C for 10
minutes, followed by 45 cycles of 95°C for 10 seconds
(ramp rate 4.4°C/second), 60°C for 30 seconds (ramp
rate 2.2°C/second) and 72°C for 1 second (ramp rate
4.4°C/second). Following amplification phase, a cooling
step was performed at 40°C for 30 seconds (ramp rate
of 2.2°C/ second). Acquisition of the fluorescence signal
was performed using Mono Hydrolysis Probe setting
(465-510 nm) following the 72°C extension phase of
each cycle. All samples were carried out in triplicate.
The CaSki (American Type Culture Collection;
Manassas, Virginia, USA) cervical adenocarcinoma cell
line was used to develop standard curves for both the
HPV16 (600 copies/genome) and GAPDH (2 copies/gen-
ome) genes. The GH354 (American Type Culture Collec-
tion; Manassas, Virginia, USA) cervical adenocarcinoma
cell line was used to develop the standard curves for
HPV18 (200 copies/genome). DNA extracted from CaSki
and GH354 cells were serially diluted tenfold starting at
50 ng to 0.0005 ng [81] Quantification was achieved using
Cycle Threshold (CT) measured with the second derivative
maximum method (LightCycler 480 Software version
1.5.0.39; Roche Applied Sciences: Indianapolis, Indiana,
USA). Saliva samples > 0.001 copy/genome were consid-
ered HPV positive. Specificity analysis was performed on
qPCR assay against HPV18 and found to be 100% specific
(data not shown).
Statistical evaluation
Sensitivity and specificity were calculated as the propor-
tion of true positives and true negatives (cutoff
value >0.001 copies/genome), respectively. Following the
acquisition of saliva samples and HPV screening results,
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pared with the overall demographic profile of the local
population using a chi-square (χ2) test, to determine if
any characteristic (gender, race, age) was different than
expected among the subjects evaluated in this study
(n = 118). A probability level of alpha (α) = 0.05 was
used to determine statistical significance.
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